An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

BACKGROUND: Although iron chelation has garnered attention as a novel therapeutic strategy for cancer, higher levels of efficacy need to be achieved. In the present study, we examined the combinatorial effect of deferoxamine (DFO), an iron chelator, and α-cyano-4-hydroxy cinnamate (CHC), a suppresso...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisawa, Koichi, Takami, Taro, Matsumoto, Toshihiko, Yamamoto, Naoki, Yamasaki, Takahiro, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103045/
https://www.ncbi.nlm.nih.gov/pubmed/35550011
http://dx.doi.org/10.1186/s40170-022-00284-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103045/
https://www.ncbi.nlm.nih.gov/pubmed/35550011
http://dx.doi.org/10.1186/s40170-022-00284-x

Ejemplares similares